

## **OPEN ACCESS**

EDITED AND REVIEWED BY Yixin Zhang, First Affiliated Hospital of Chongqing Medical University, China

\*CORRESPONDENCE
Ling Zhao

☑ zhaoling@cdutcm.edu.cn
Dingjun Cai

☑ djcai@cdutcm.edu.cn

<sup>†</sup>These authors have contributed equally to this

RECEIVED 27 February 2023 ACCEPTED 04 April 2023 PUBLISHED 20 April 2023

### CITATION

Liu L, Qi W, Wang Y, Ni X, Gao S, Zhou Z, Chen D, He Z, Sun M, Wang Z, Cai D and Zhao L (2023) Corrigendum: Circulating exosomal microRNA profiles in migraine patients receiving acupuncture treatment: a placebo-controlled clinical trial. *Front. Mol. Neurosci.* 16:1174810. doi: 10.3389/fnmol.2023.1174810

## COPYRIGHT

© 2023 Liu, Qi, Wang, Ni, Gao, Zhou, Chen, He, Sun, Wang, Cai and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Circulating exosomal microRNA profiles in migraine patients receiving acupuncture treatment: a placebo-controlled clinical trial

Lu Liu<sup>1†</sup>, Wenchuan Qi<sup>1,2†</sup>, Yanan Wang<sup>1</sup>, Xixiu Ni<sup>1</sup>, Shan Gao<sup>1</sup>, Ziyang Zhou<sup>1</sup>, Daohong Chen<sup>1</sup>, Zhenxi He<sup>1</sup>, Mingsheng Sun<sup>1</sup>, Ziwen Wang<sup>1</sup>, Dingjun Cai<sup>1,2\*</sup> and Ling Zhao<sup>1,2\*</sup>

<sup>1</sup>Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China, <sup>2</sup>Acupuncture and Chronobiology Key Laboratory of Sichuan Province, Chengdu, Sichuan, China

KEYWORDS

acupuncture, migraine, biomarker, exosome, miRNA

# A corrigendum on

Circulating exosomal microRNA profiles in migraine patients receiving acupuncture treatment: a placebo-controlled clinical trial

Liu, L., Qi, W., Wang, Y., Ni, X., Gao, S., Zhou, Z., Chen, D., He Z., Sun, M., Wang, Z., Cai, D., and Zhao, L. (2023). *Front Mol Neurosci.* 15:1098766. doi: 10.3389/fnmol.2022.1098766

In the published article, there was an error in Table 2 as published. The prognostic biomarker hsa-miR-550a-3-5p should be corrected to hsa-miR-145-5p, and hsa-miR-4732-5p should be corrected to hsa-miR-5010-3p. The corrected Table 2 and its caption appear below.

In the published article, there was an error in Supplementary Table 1. We mistakenly used "has-miR" instead of "hsa-miR." Therefore, we corrected Has-miR-145-5p-R and Has-miR-145-5p-F to Hsa-miR-145-5p-R and Hsa-miR-145-5p-F. The correct material statement has been updated in the original article.

In the published article, there was an error. A correction has been made to Section 3.3 **Exosomal miRNA profile of HCs and MWoA patients by small RNA sequencing**. The number of miRNAs consistently detected in both healthy controls and MWoA patients in section 3.3 is 388, not 338 as mentioned in the article.

The corrected sentence appears below:

"[Notably, there were 388 miRNAs consistently detected in both HCs and MWoA patients]".

In the published article, there was an error. We mistakenly used "has-miR" instead of "hsa-miR" in our article. Therefore, we corrected all instances of "has-mir" to "hsa-mir" in the manuscript.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Liu et al. 10.3389/fnmol.2023.1174810

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Liu et al. 10.3389/fnmol.2023.1174810

TABLE 2 Prediction power of serum exosomal miRNAs for the diagnosis and prognosis of MWoA patients.

miRNA	Accuracy (95% CI)	p-value
Diagnosis		
hsa-miR-4732-5p	1.00 (0.88-1.00)	0
hsa-miR-369-5p	0.83 (0.65-0.94)	0.0355
hsa-miR-375	0.90 (0.73-0.98)	0.0033
hsa-miR-550a-3-5p	0.90 (0.73-0.98)	0.0033
hsa-miR-145-5p	0.93 (0.78-0.99)	0.0007
hsa-miR-5010-3p	0.93 (0.78-0.99)	0.0007
Prognosis		
hsa-miR-369-5p	0.95 (0.74–1.00)	0.068
hsa-miR-145-5p	0.89 (0.67-0.99)	0.2042
hsa-miR-5010-3p	1.00 (0.82-1.00)	0.0112
hsa-miR-378c	0.95 (0.74–1.00)	0.068
hsa-miR-1292-5p	0.95 (0.74–1.00)	0.068